Cytokines are very fashionable at big pharma. Met
Post# of 145808
![](/assets/46931549/no_avatar_available_thumb.jpg)
"IL-2 has long been notorious as a target. While the cytokine can activate immune cells against cancer, those effects are a double-edged sword, triggering dangerous side effects for patients. Multiple companies have struggled to tread the fine line between safety and efficacy — with Nektar representing the latest and perhaps most high-profile implosion when it shuttered its Bristol Myers Squibb-partnered program.
Sanofi takes $1.6B hit on IL-2
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)